Search Results - "Gurevich, E.V."

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder by Bychkov, E.R, Ahmed, M.R, Gurevich, V.V, Benovic, J.L, Gurevich, E.V

    Published in Neurobiology of disease (01-11-2011)
    “…Abstract Alterations of multiple G protein-mediated signaling pathways are detected in schizophrenia. G protein-coupled receptor kinases (GRKs) and arrestins…”
    Get full text
    Journal Article
  2. 2

    Arrestin-1 expression level in rods: balancing functional performance and photoreceptor health by Song, X, Vishnivetskiy, S.A, Seo, J, Chen, J, Gurevich, E.V, Gurevich, V.V

    Published in Neuroscience (03-02-2011)
    “…Abstract In rod photoreceptors, signaling persists as long as rhodopsin remains catalytically active. Phosphorylation by rhodopsin kinase followed by…”
    Get full text
    Journal Article
  3. 3

    Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia by Bychkov, E.R, Gurevich, V.V, Joyce, J.N, Benovic, J.L, Gurevich, E.V

    Published in Neurobiology of aging (01-03-2008)
    “…Abstract Arrestins and G proteins-coupled receptor kinases (GRKs) regulate signaling and trafficking of G protein-coupled receptors. We investigated changes in…”
    Get full text
    Journal Article
  4. 4

    l-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain by Bezard, E., Gross, C.E., Qin, Li, Gurevich, V.V., Benovic, J.L., Gurevich, E.V.

    Published in Neurobiology of disease (01-03-2005)
    “…Dysregulation of dopamine receptors (DARs) is believed to contribute to Parkinson disease (PD) pathology. G protein-coupled receptors (GPCR) undergo…”
    Get full text
    Journal Article
  5. 5

    Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors by Guigoni, C., Aubert, I., Li, Q., Gurevich, V.V., Benovic, J.L., Ferry, S., Mach, U., Stark, H., Leriche, L., Håkansson, K., Bioulac, Bernard H., Gross, Christian E., Sokoloff, Pierre, Fisone, Gilberto, Gurevich, E.V., Bloch, Bertrand, Bezard, Erwan

    Published in Parkinsonism & related disorders (01-06-2005)
    “…Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa therapy for Parkinson's disease. Taking advantage of a monkey brain…”
    Get full text
    Journal Article Conference Proceeding
  6. 6

    Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development by Gurevich, E.V, Benovic, J.L, Gurevich, V.V

    Published in Neuroscience (01-01-2002)
    “…Arrestins are adaptor proteins involved in homologous desensitization and trafficking of G protein-coupled receptors. Arrestins bind to activated…”
    Get full text
    Journal Article
  7. 7

    Loss of response to levodopa in Parkinson’s disease and co-occurrence with dementia: role of D 3 and not D 2 receptors by Joyce, J.N, Ryoo, H.L, Beach, T.B, Caviness, J.N, Stacy, Mark, Gurevich, E.V, Reiser, Mark, Adler, C.H

    Published in Brain research (15-11-2002)
    “…Previous data suggest a relationship between the loss of response to levodopa in Parkinson’s disease (PD) patients with the co-occurrence of dementia, but the…”
    Get full text
    Journal Article
  8. 8

    Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors by JOYCE, J. N, RYOO, H. L, BEACH, T. B, CAVINESS, J. N, STACY, Mark, GUREVICH, E. V, REISER, Mark, ADLER, C. H

    Published in Brain research (15-11-2002)
    “…Previous data suggest a relationship between the loss of response to levodopa in Parkinson's disease (PD) patients with the co-occurrence of dementia, but the…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11
  12. 12

    Ventral striatal D 3 receptors and Parkinson's Disease by Joyce, J.N., Ryoo, H., Gurevich, E.V., Adler, C., Beach, T.

    Published in Parkinsonism & related disorders (01-07-2001)
    “…Antiparkinsonian drugs are thought to act largely through the D2 receptor family that includes the D 2 and D 3 receptors. D 2 and D 3 receptors exhibit both…”
    Get full text
    Journal Article
  13. 13
  14. 14